Liu W F
Laboratory of Behavioral Pharmacology and Toxicology, CSIST, Lung-Tan, Taiwan, R.O.C.
Pharmacol Biochem Behav. 1991 Dec;40(4):745-9. doi: 10.1016/0091-3057(91)90079-h.
We have previously reported that acute oral administration of low doses (less than or equal to 12 mg/kg) of pyridostigmine bromide (PYR) to rats resulted in a dose-dependent decrement in reinforcement rate under two different multiple schedules of response-produced water presentation, which involved motivational dysfunction rather than motor impairment and alterations in visual perception. The purpose of the present investigation was to examine further if the anticipated operant behavioral deficits of PYR are mediated by central and/or peripheral cholinergic mechanisms. Lever-press responses of male Sprague-Dawley rats were maintained under a multiple fixed-ratio GO/differential-reinforcement-of-low-rate NO GO, brightness discrimination, schedule of water reinforcement. The effects of the muscarinic antagonists atropine (ATR) and methylatropine (MAT), both at doses of 0.25, 0.5 and 1.0 mg/kg (SC), against a single oral low dose of PYR (12 mg/kg)-induced behavioral disruption were compared. ATR partially antagonized the reinforcement loss of PYR with concomitant dose-related increases in nonreinforced responses, whereas MAT completely antagonized the reinforcement loss without affecting the frequency of nonreinforced responses. These results suggest that in rats, the debilitating effects of oral PYR on operant behavior are primarily due to the stimulation of peripheral muscarinic receptors via its anticholinesterase activity. The increments of nonreinforced responses observed after coadministration of PYR with ATR may reflect a central, excitatory action of ATR which could affect the discrimination performance. The present results have practical implications for the clinical utilization of PYR in combination with the peripherally active muscarinic antagonist in situations where optimal performance is required.
我们之前曾报道,对大鼠急性口服低剂量(小于或等于12毫克/千克)的溴吡斯的明(PYR),在两种不同的由反应产生水的多重强化程序下,会导致强化率呈剂量依赖性下降,这涉及动机功能障碍而非运动损伤以及视觉感知改变。本研究的目的是进一步探究PYR预期的操作性行为缺陷是否由中枢和/或外周胆碱能机制介导。雄性Sprague-Dawley大鼠的杠杆按压反应在多重固定比率GO/低比率差别强化NO GO、亮度辨别、水强化程序下维持。比较了毒蕈碱拮抗剂阿托品(ATR)和甲基阿托品(MAT),剂量均为0.25、0.5和1.0毫克/千克(皮下注射),对抗单次口服低剂量PYR(12毫克/千克)诱导的行为破坏的效果。ATR部分拮抗了PYR的强化损失,同时非强化反应随剂量相关增加,而MAT完全拮抗了强化损失,且不影响非强化反应的频率。这些结果表明,在大鼠中,口服PYR对操作性行为的削弱作用主要是由于其抗胆碱酯酶活性刺激外周毒蕈碱受体所致。PYR与ATR共同给药后观察到的非强化反应增加可能反映了ATR的中枢兴奋性作用,这可能会影响辨别性能。本研究结果对于在需要最佳性能的情况下将PYR与外周活性毒蕈碱拮抗剂联合临床应用具有实际意义。